Morgan Stanley Raises PT for CG Oncology to $56, Maintains Overweight Rating

Morgan Stanley Raises PT for CG Oncology to $56, Maintains Overweight Rating

June 17, 2025 - Morgan Stanley has updated its price target for CG Oncology (NYSE:CGO) to $56, maintaining an overweight rating. The new target represents a 25% increase from the previous price target of $45. The analysts at Morgan Stanley believe that CG Oncology's strong pipeline and strategic focus on oncology treatments offer significant growth potential.

The analysts highlighted CG Oncology's recent developments, including the successful launch of its new drug, CG-001, and the company's ongoing clinical trials for other promising therapies. They also noted the company's strong cash position and the potential for additional licensing deals to bolster its revenue streams.

Morgan Stanley's new price target reflects the analysts' confidence in CG Oncology's ability to capitalize on the growing demand for innovative cancer treatments. The company's focus on precision medicine and its partnerships with leading pharmaceutical companies position it well to capture a significant share of the oncology market.

CG Oncology's stock has been trading at around $40 in recent weeks, providing a 40% discount to the new price target. This suggests that investors may be undervaluing the company's growth prospects. However, the analysts caution that the market's perception of the company's valuation could be influenced by broader economic conditions and geopolitical factors.

In other recent news, CG Oncology has been actively expanding its clinical trial network and has secured additional funding from venture capital firms to support its research and development efforts. The company's strategic partnerships with major pharmaceutical companies also underscore its commitment to bringing innovative treatments to market.

Morgan Stanley's positive outlook on CG Oncology is supported by the company's strong financial performance and its robust pipeline of promising therapies. The analysts believe that the company's ability to execute on its strategic plans and capitalize on emerging opportunities will drive long-term shareholder value.

References:
[1] https://au.investing.com/news/analyst-ratings/morgan-stanley-initiates-centene-stock-with-overweight-rating-93CH-3881251
[2] https://www.marketbeat.com/instant-alerts/filing-morgan-stanley-nysems-shares-acquired-by-qrg-capital-management-inc-2025-06-16/